These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17107349)

  • 1. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
    Imai N; Shikami M; Miwa H; Suganuma K; Hiramatsu A; Watarai M; Satoh A; Itoh M; Imamura A; Mihara H; Nitta M
    Br J Haematol; 2006 Dec; 135(5):673-82. PubMed ID: 17107349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor.
    Imai N; Miwa H; Shikami M; Suganuma K; Gotoh M; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Shitara K; Shibuya M; Nitta M
    Leuk Res; 2009 Dec; 33(12):1650-7. PubMed ID: 19342098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
    List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
    Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML.
    Hiramatsu A; Miwa H; Shikami M; Ikai T; Tajima E; Yamamoto H; Imai N; Hattori A; Kyo T; Watarai M; Miura K; Satoh A; Itoh M; Imamura A; Mihara H; Katoh Y; Nitta M
    Leuk Lymphoma; 2006 Jan; 47(1):89-95. PubMed ID: 16465716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells.
    Xu Z; Maiti D; Kisiel W; Duh EJ
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2819-25. PubMed ID: 17023682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer.
    Xia G; Kumar SR; Hawes D; Cai J; Hassanieh L; Groshen S; Zhu S; Masood R; Quinn DI; Broek D; Stein JP; Gill PS
    J Urol; 2006 Apr; 175(4):1245-52. PubMed ID: 16515971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activation of signal transducers and activators of transcription induced by vascular endothelial growth factor in CD34+ hematopoietic progenitor cells in vitro].
    Ye F; Ye DF; Xie X; Chen HZ; Lü WG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):12-7. PubMed ID: 15052767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-redundant roles of the Gab1 and Gab2 scaffolding adapters in VEGF-mediated signalling, migration, and survival of endothelial cells.
    Caron C; Spring K; Laramée M; Chabot C; Cloutier M; Gu H; Royal I
    Cell Signal; 2009 Jun; 21(6):943-53. PubMed ID: 19233262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
    Böhm A; Aichberger KJ; Mayerhofer M; Herrmann H; Florian S; Krauth MT; Derdak S; Samorapoompichit P; Sonneck K; Vales A; Gleixner KV; Pickl WF; Sperr WR; Valent P
    Eur J Clin Invest; 2009 May; 39(5):395-405. PubMed ID: 19320940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
    Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
    Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
    Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
    Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation.
    Saulle E; Riccioni R; Coppola S; Parolini I; Diverio D; Riti V; Mariani G; Laufer S; Sargiacomo M; Testa U
    Br J Haematol; 2009 May; 145(3):399-411. PubMed ID: 19245429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FHL-2 suppresses VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1.
    Hayashi H; Nakagami H; Takami Y; Koriyama H; Mori M; Tamai K; Sun J; Nagao K; Morishita R; Kaneda Y
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):909-14. PubMed ID: 19325137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
    Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
    Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xanthine oxidase interaction with vascular endothelial growth factor in human endothelial cell angiogenesis.
    Kou B; Ni J; Vatish M; Singer DR
    Microcirculation; 2008 Apr; 15(3):251-67. PubMed ID: 18386220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.